Esophageal Cancer- Pipeline Insight, 2025

This “Esophageal Cancer- Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Esophageal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Esophageal Cancer: Understanding

Esophageal Cancer: Overview

Esophageal cancer is a malignancy that occurs in the esophagus, the long, hollow tube that runs from the throat to the stomach, responsible for moving swallowed food to the stomach for digestion. This type of cancer is relatively rare but has a high mortality rate due to often being diagnosed at a late stage. There are two primary types of esophageal cancer: squamous cell carcinoma, which arises from the squamous cells lining the esophagus, and adenocarcinoma, which originates from glandular cells and is more commonly found in the lower part of the esophagus. Esophageal cancer often presents with symptoms that can be mistaken for less serious conditions, contributing to delays in diagnosis. Common signs and symptoms include difficulty swallowing (dysphagia), unintentional weight loss, chest pain or discomfort, persistent cough or hoarseness, and regurgitation of food. In advanced stages, patients may experience bleeding in the esophagus, leading to anemia, or the presence of black, tarry stools.

The exact cause of esophageal cancer is not fully understood, but several risk factors have been identified. These include chronic gastroesophageal reflux disease (GERD), Barrett's esophagus (a condition in which the esophageal lining changes due to acid exposure), smoking, heavy alcohol consumption, obesity, and a diet low in fruits and vegetables. Genetic mutations and damage to the DNA of esophageal cells play a crucial role in the development of cancer, leading to uncontrolled cell growth and tumor formation.

Diagnosis of esophageal cancer typically involves a combination of endoscopic procedures, imaging studies, and biopsy. An upper endoscopy allows direct visualization of the esophagus and enables biopsy of suspicious areas. Imaging studies such as a barium swallow X-ray, CT scan, PET scan, and endoscopic ultrasound (EUS) are used to determine the extent of the disease and whether it has spread to other parts of the body. Biopsy samples are examined under a microscope to confirm the presence of cancer cells and identify the type of esophageal cancer.

Treatment for esophageal cancer depends on the stage of the disease, the patient’s overall health, and the specific characteristics of the tumor. Early-stage cancer may be treated with endoscopic procedures, such as endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD), to remove small tumors. Advanced stages often require a combination of surgery, chemotherapy, and radiation therapy. Esophagectomy, the surgical removal of part or all of the esophagus, is a common treatment for resectable tumors. Chemoradiation, a combination of chemotherapy and radiation therapy, is often used to shrink tumors before surgery or as the primary treatment in inoperable cases. Targeted therapies and immunotherapies are emerging treatment options, offering hope for improved outcomes in patients with advanced esophageal cancer. Palliative care is also an essential aspect of treatment, aiming to relieve symptoms and improve quality of life for patients with advanced disease.

'Esophageal Cancer- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Esophageal Cancer pipeline landscape is provided which includes the disease overview and Esophageal Cancer treatment guidelines. The assessment part of the report embraces, in depth Esophageal Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Esophageal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Esophageal Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Esophageal Cancer.

Esophageal Cancer Emerging Drugs Chapters

This segment of the Esophageal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Esophageal Cancer Emerging Drugs

• S-588410: OncoTherapy Science, Inc. /Shionogi & Co. S-588410 is cancer peptide vaccine licensed out from OncoTherapy to Shionogi & Co., Ltd. It is a subunit vaccine commercialized by Shionogi. It is administered subcutaneously as an emulsion. The therapeutic candidate is a mixed peptide-cocktail vaccine of S-288310 and S-488410 comprising of five human leukocyte antigens (HLA)-A 2402-restricted epitope peptides derived from oncoantigen. The drug candidate is a new molecular entity. Currently, the drug is in the Phase III stage of its development for the treatment of Esophageal Cancer.

Telomelysin: Oncolys BioPharma Inc

Telomelysin (OBP-301) is a gene-modified oncolytic adenovirus in which selectively replicate in cancer cells by introducing human telomerase reverse transcriptase (hTERT) promotor. From the result of Phase I clinical study in the US, Telomelysin showed abscopal effect, which non-injected tumor as well as injected tumor was regressed in melanoma patients after single injection into one single tumor and found that not only increasing infiltration of CD8 and antigen presenting cells but diminishing Treg cells in injected tumor site. In preclinical studies for Telomelysin, Oncolys has demonstrated effective anti-tumor activity on various cancer cells, and there was no finding that may bring safety concerns in toxicological studies as well as bio-distribution study. Currently, the drug is in the Phase II stage of its development for the treatment of Esophageal Cancer.

LVGN-6051: Lyvgen Biopharma

LVGN6051 is xLinkAb anti-4-1BB (CD137) agonist mAb that has been designed to activate 4-1BB optimally in tumor microenvironment by targeting both 4-1BB and FcγRIIB. LVGN6051 strikes a balance between antitumor efficacy and safety by agonizing 4-1BB only in the presence of FcγRIIB, which is expressed on immune cells enriched in the tumor microenvironment, including B cells, dendritic cells and granulocytes.. Currently, the drug is in the Phase I stage of its development for the treatment of Esophageal Cancer.

AN-0025: Adlai Nortye Biopharma

AN0025 is a small molecule prostaglandin E receptor 4 (EP4) antagonist, discovered by Eisai Co., Ltd. (Eisai), designed to modulate the tumor microenvironment. Adlai Nortye has been granted exclusive rights concerning the research, development, manufacture and marketing in all regions outside of Japan and part of Asia (excluding China) by Eisai. It is currently under development for the treatment of locally advanced rectal cancer with radiation therapy in the ongoing global Phase II ARTEMIS study. We presented Phase 1b results for this indication at the European Society for Medical Oncology (“ESMO”) in October 2019, where combination therapy with AN0025 and RT/CRT was safe and enabled 36% of patients to achieve either a cCR or pathologic complete response (pCR). Currently, the drug is in the Phase I stage of its development for the treatment of Esophageal Cancer.

Esophageal Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Esophageal Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Esophageal Cancer

There are approx. 80+ key companies which are developing the therapies for Esophageal Cancer. The companies which have their Esophageal Cancer drug candidates in the most advanced stage, i.e. Phase III include, OncoTherapy Science, Inc. /Shionogi & Co.

Phases

The report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Esophageal Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Esophageal Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Esophageal Cancer drugs.

Esophageal Cancer Report Insights

• Esophageal Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Esophageal Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Esophageal Cancer drugs?
• How many Esophageal Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Esophageal Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Esophageal Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Esophageal Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• OncoTherapy Science, Inc. /Shionogi & Co.,
• Oncolys BioPharma Inc
• Lyvgen Biopharma
• Adlai Nortye Biopharma
• NovaRock Biotherapeutics
• Genmab
• Genentech
• Jiangsu HengRui Medicine
• Taiho Pharmaceutical
• Mirati Therapeutics
• Boehringer Ingelheim
• Suzhou Zelgen Biopharmaceuticals
• Active Biotech/NeoTX Therapeutics
• Rakuten Medical
• HLB
• CDR-Life
• Schrodinger
• BioSyngen
• Guangzhou Bio-gene Technology
• GO Therapeutics

Key Products

• S-588410
• Telomelysin
• LVGN-6051
• AN-0025
• Anti-Nectin4/CD137 bispecific antibody
• Amivantamab
• Tiragolumab
• Trastuzumab rezetecan
• Retlirafusp alfa
• Atezolizumab
• Tipiracil/trifluridine
• Sitravatinib
• Afatinib
• Donafenib
• Naptumomab estafenatox
• Cetuximab sarotalocan
• Rivoceranib
• CDR 404
• SGR 2921
• BGT 007
• BG 1807
• GO 8H3

This product will be delivered within 3-5 business days.